Jumpcode Genomics: Jon Armstrong, Kerri McWeeny, Jonathan Bell
Jumpcode Genomics has appointed Jon Armstrong as vice president of research and development, Kerri McWeeny as vice president of marketing, and Jonathan Bell as vice president of sales.
Armstrong most recently served as CSO for Cofactor Genomics, which he also cofounded. Prior to his role at Cofactor Genomics, Armstrong spent nearly a decade in Elaine Mardis' lab at the MCDonnell Genome Institute of Washington University in St. Louis, where he helped develop microarray, next-generation sequencing, molecular biology, and cancer genetics technologies.
McWeeny previously served as a senior director in marketing at Illumina. She joined Illumina in 2012 and held leadership roles in global pricing strategy, marketing strategy, and communications throughout her tenure there. Prior to Illumina, she held commercial leadership roles at Mo Bio Laboratories and GenVault Corp, as well as research and development roles at Motorola Life Sciences and Abbott Laboratories.
Bell has held positions in sales, product marketing, and regional marketing for life sciences companies such as Affymetrix, Illumina, and 10x Genomics. He most recently served as a VP for Celsee, before it was acquired by Bio-Rad.
Quantum-Si: Michael Mina
Single-molecular proteomics firm Quantum-Si has appointed Michael Mina as chief medical advisor. Mina is assistant professor of epidemiology, immunology, infectious diseases, and pathology at the Harvard TH Chan School of Public Health and Harvard Medical School. He is also a professor and associate medical director in clinical pathology at Brigham and Women's Hospital at Harvard Medical School. He holds an MD and PhD from Emory University and competed his postdoc in infectious diseases at Princeton University and Harvard Med.
Quanterix: Laurie Olson
Quanterix has appointed Laurie Olson to its board of directors effective April 27. Olson most recently served as executive vice president for strategy and commercial operations at Pfizer and a member of Pfizer's executive leadership team until 2018. She currently serves on the board of directors of Karuna Therapeutics.
SeqWell: Dan Calvo
SeqWell, a Beverly, Massachusetts-based provider of next-generation sequencing library construction technologies, has named appointed Dan Calvo as president and CEO, effective April 19. Calvo most recently served as president and and CEO of Gyros Protein Technologies from 2013 through its acquisition by Mesa Labs in 2019. Prior to that, he was president and CEO of Oncimmune from 2009 to 2013. Calvo also previously served as CEO at Cellomics and Assay Designs, through their acquisitions by Fisher Scientific an Enzo Biochem, respectively.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.